New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

In what situations would you consider ESAs in hospitalized patients with severe anemia for indications other than CKD or myelosuppressive chemotherapy (e.g., ACD, hemorrhage)?

Practice is variable in the community, with some hematologists frequently prescribing ESAs for severe anemia that is mostly inflammatory. Do the risks (e.g., thrombosis) outweigh the benefits (avoiding transfusion)?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Ohio State University
Answered on

In deciding on the risk-benefit of ESAs in patients with severe anemia due to bleeding and/or inflammatory disease, there are two considerations. The first is the severity of the anemia and consequently, the time to initial response. Using the standard dose of ESAs, it may take 8 to 12 weeks to achieve the target hemoglobin of 10 g. Thus, patients with severe anemia who need a rise in hemoglobin quickly may not benefit from ESAs. However, high-intensity treatment with ESA may achieve a rapid response but with the risk of thrombotic complications.

Thus, in our patients, we do not consider ESAa in patients with prior thrombosis, current history of cancer, or need for a rapid rise in hemoglobin. Moreover, we would only consider ESAs if there i...

Join for free or sign in to see the full answer